7:30 am Morning Registration & Light Breakfast
8:25 am Chairs Opening Remarks
Establishing Standardized & Optimized Frameworks to Enable Reliable, Reproducible Results for Accelerated Liquid Biopsy Adoption
8:30 am Enhancing Collaboration & Harmonization in Liquid Biopsy Surveillance: A BLOODPAC Perspective
Synopsis
- Highlighting key strategies to foster collaboration among stakeholders in liquid biopsy research
- Introducing the new lexicon designed to standardize terminology and practices across the liquid biopsy field
Updated Information
9:00 am Session Reserved for: Foundation Medicine
9:30 am Diagnostic Landscape in Rare Diseases: Strategies to Improve Patient’s Journey & Outcomes
Synopsis
- Challenges of diagnosis in rare diseases therapeutic areas and clinical trials designs
- Insights into development and validation of diagnostics strategies, adoption and impact
- Identifying collaboration and harmonizing global access to improve diagnostic guidelines and patients care
Rare Disease
10:00 am Panel Discussion:Accelerating Liquid Biopsy Application to Real-World Settings with Standardized Protocols & Measures
Synopsis
• Developing universal measures to gain confidence in liquid biopsy testingÂ
• What are best strategies for applying liquid biopsy insights from controlled trials to diverse, real-world patient populations?
• What are the actionable frameworks to help healthcare providers integrate liquid biopsy protocols seamlessly into existing diagnostic workflows?
10:30 am Speed Networking Session
Synopsis
As the Liquid Biopsy community unites again, this valuable session will ensure that you can connect
with your peers in the room to make new and lasting connections. All attendees will have the
opportunity to meet and network with their industry peers.
Driving Early Intervention & Personalised Monitoring Through Biomarker Innovation in Oncology
11:30 am Integrating Biomarker Insights to Guide Dose Selection & Monitor Therapeutic Response in Immuno-Oncology
Synopsis
- How iitune-1 trial utilizes comprehensive biomarker analysis to guide dose selection
- How plasma biomarkers, RNA seq analysis contribute to evaluating innate and adaptive immune responses
- Retrospective analysis into how ctDNA changes correlate with clinical outcomes, to provide insights in its value in monitoring therapeutic efficacy
Immuno-Oncology
12:00 pm Session Reserved for: Natera
12:30 pm ctDNA Analysis Enhances MRI-Based (RECIST) Assessment of Response in Clinical Trial of Second-Line Advanced HCC
Synopsis
- ctDNA highlights molecular responses to resolve lack of clarity from MRI images alone
- Combining ctDNA with MRI allows for broader, and earlier, detection of response in second-line advanced HCC to enhance clinical trial readout
- ctDNA-guided monitoring supports ongoing personalized treatment to improve optimize patient outcomes by elucidating potential basis for immune escape and offering design guidance for updated therapeutics
Personalized Cancer Vaccines
1:00 pm Panel Discussion: Unlocking the Full Potential of Tissue-Free, Methylation-Based Liquid Biopsies to Redefine Monitoring
Synopsis
- The logistical and clinical limitations of tissue-informed methods, including time to treatment, tissue availability, and turnaround time
- How methylation signatures may offer higher sensitivity and broader applicability than variant tracking alone
- Considerations for clinical validation, regulatory frameworks, and payer acceptance of tissue-free MRD solutions
1:30 pm Lunch & Networking Break
Advancing MRD as a Surrogate Endpoint to Streamline Trial Readouts in Hematology
2:30 pm Translating MRD Success in Hematologic Cancers to Solid Tumors to Expand MRD Impact & Accelerate Clinical Trials
Synopsis
- Exploring the role of minimal residual disease (MRD) in enhancing treatment strategies for hematologic cancers
- Leveraging MRD insights to optimize personalized therapies, improving patient outcomes and reducing relapse risks
- Discussing cutting-edge approaches to MRD detection and their impact on clinical decision-making in hematologic cancer management
Hematology
3:00 pm Session Reserved for: SAGA Diagnostics
3:30 pm Defining Tumor & Immune Markers to Stratify Patients at Risk of Developing Multiple Myeloma from MGUS & Smoldering Myeloma
Synopsis
- It is feasible of developing biomarkers from liquid biopsies in ALL and AML as evidenced from 2 projects in hematologic conditions
- MRD can be used as a prognostic indicator. Efforts are underway to develop biomarkers for progression from MGUS to Multiple Myeloma
- Inclusion of patient advocacy groups and patients with lived experience provides valuable insight into patient needs and needed data to improve patient outcomes
Hematology
4:00 pm Afternoon Networking Break
Empowering Pathology: Enhancing Liquid Biopsy Precision Through Collaboration & Digital Innovation
4:30 pm Bridging the Gap of the Role of Pathologists in Advancing Liquid Biopsy for Precision Oncology
Synopsis
- How can pathologists collaborate more effectively with biopharma and oncologists to optimize biomarker-driven clinical trials and improve treatment decision-making?
- What are the key challenges in ensuring pathologists play a central role in determining when and how liquid biopsy should be integrated into clinical workflows, and how can their involvement be enhanced?
- How can digital pathology and molecular techniques strengthen the role of pathologists in patient stratification and resistance monitoring through liquid biopsy applications?
Pathology
5:00 pm Transforming Patient Care Through Digital Pathology Innovations in Clinical Trials
Synopsis
- Evolving role of pathologist in cancer patient care
- The challenges of patient selection in current biomarker testing landscape
- Facilitate trial success through implementation of pathology
Digital Pathology